Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
February 20 2024 - 7:00AM
Business Wire
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, today announced that it plans to release
financial results for the fourth quarter and full year ended
December 31, 2023 on March 5, 2024. The Company will host a
conference call at 4:30 p.m. E.T. on March 5, 2024, to provide a
business update and discuss financial results.
Tuesday, March 5, 4:30 p.m.
E.T.
Domestic: (888) 550-5280 International: (646) 960-0813 Webcast
Registration: https://events.q4inc.com/attendee/513453609
Conference ID: 2696394
An archived version of the call will be available approximately
two hours after the completion of the event on the Marinus website
at ir.marinuspharma.com/events-and-presentations.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated
to the development of innovative therapeutics for seizure
disorders. The Company first introduced FDA-approved prescription
medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in
2022 and continues to invest in the potential of ganaxolone in IV
and oral formulations to maximize therapeutic reach for adult and
pediatric patients in acute and chronic care settings. For more
information about Marinus visit www.marinuspharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240220631175/en/
Company Contacts Investors
Jim DeNike Senior Director, Investor Relations Marinus
Pharmaceuticals, Inc. jdenike@marinuspharma.com
Media Molly Cameron Director,
Corporate Communications & Investor Relations Marinus
Pharmaceuticals, Inc. mcameron@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Apr 2023 to Apr 2024